First-line treatment for advanced CRC typically involves combination chemotherapy regimens, including FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan), often administered with targeted biologics such as the VEGF-A inhibitor bevacizumab or the EGFR inhibitors cetuximab and panitumumab, the latter restricted to RAS wild-type tumors. The gene discussed is EGFR; the disease is colorectal carcinoma.